Century Therapeutics, Inc. (NASDAQ:IPSC) Insider Gregory Russotti Sells 5,000 Shares of Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) insider Gregory Russotti sold 5,000 shares of the stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $3.10, for a total transaction of $15,500.00. Following the completion of the transaction, the insider now directly owns 297,319 shares of the company’s stock, valued at approximately $921,688.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Century Therapeutics Price Performance

Shares of IPSC stock opened at $2.96 on Thursday. Century Therapeutics, Inc. has a 12-month low of $1.28 and a 12-month high of $5.51. The firm has a fifty day moving average of $4.10 and a 200-day moving average of $3.13.

Century Therapeutics (NASDAQ:IPSC) last announced its earnings results on Thursday, March 14th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.07. Century Therapeutics had a negative net margin of 6,115.12% and a negative return on equity of 54.73%. The firm had revenue of $0.27 million during the quarter, compared to analyst estimates of $1.69 million. Equities analysts predict that Century Therapeutics, Inc. will post -1.94 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Piper Sandler reiterated an “overweight” rating and issued a $9.00 price objective (down from $10.00) on shares of Century Therapeutics in a research report on Friday, April 12th. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Century Therapeutics in a report on Friday, March 15th. Finally, Canaccord Genuity Group raised their target price on Century Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, March 15th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $13.60.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Abel Hall LLC bought a new position in shares of Century Therapeutics in the fourth quarter valued at about $33,000. Federated Hermes Inc. grew its position in shares of Century Therapeutics by 0.4% in the fourth quarter. Federated Hermes Inc. now owns 618,482 shares of the company’s stock valued at $2,053,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Avidity Partners Management LP increased its stake in shares of Century Therapeutics by 23.4% during the fourth quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock worth $4,499,000 after purchasing an additional 256,500 shares during the period. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.